RO 269228

Drug Profile

RO 269228

Latest Information Update: 31 Jan 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche Palo Alto LLC
  • Class Hydroxycholecalciferols; Osteoporosis therapies
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 12 Dec 2003 No development reported - Clinical-Phase-Unknown for Postmenopausal osteoporosis in USA (PO)
  • 11 Dec 2000 Investigation in Postmenopausal osteoporosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top